Login to Your Account

Axovant move SAPS value; intepirdine guillotine means answerin’ for nelotanserin

By Randy Osborne
Staff Writer

Monday, January 8, 2018

Ilise Lombardo, clinical research head of Axovant Sciences Ltd., said the firm’s ongoing efforts will “certainly be informed” by the late-stage clinical work with approved pimavanserin (Nuplazid, Acadia Pharmaceuticals Inc.) as tests proceed with similarly 5HT2A-targeting nelotanserin. “There is good information, certainly, in the pimavanserin study,” which used one of the same measures Axovant deployed: the Scale for the Assessment of Positive Symptoms in PD (SAPS-PD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription